Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02908074 · ClinicalTrials.gov registry record · Phase 2
A 6 Month Safety Extension Study of MBGS205
A Phase 2 study, sponsored by Mereo BioPharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 143
- Enrollment target
NCT02908074 is a Phase 2 study that has completed, run by Mereo BioPharma. The registered enrollment target is 143 participants.
The verdict
NCT02908074, a Phase 2 study, has completed, sponsored by Mereo BioPharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 143 participants
- Enrollment target
Study Summary
Phase IIb, multicentre, double-blind, randomised, placebo-controlled parallel-group 36-week study evaluating safety and efficacy of BGS649 in male obese subjects with hypogonadotropic hypogonadism (HH)
Interventions
- DRUG BGS649
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2016-11-15 |
| Est. Completion | 2018-11-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02908074
The ClinicalTrials.gov registry entry for NCT02908074 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mereo BioPharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BGS649 is the first listed.
NCT02908074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02908074 about?
NCT02908074 is a clinical study titled "A 6 Month Safety Extension Study of MBGS205". Phase IIb, multicentre, double-blind, randomised, placebo-controlled parallel-group 36-week study evaluating safety and efficacy of BGS649 in male obese subjects with hypogonadotropic hypogonadism (HH)
What is the current status of trial NCT02908074?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 143 participants. The study started on 2016-11-15. Estimated completion is 2018-11-21.
What interventions are being tested in trial NCT02908074?
The interventions under investigation include: BGS649 (DRUG).
Who is sponsoring clinical trial NCT02908074?
This trial is sponsored by Mereo BioPharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.